Avecia
Avecia, a part of Nitto Denko Inc.,[1] is a private biotechnology company focused on the development and manufacture of novel medicines using biotechnology techniques. Avecia operates as a contract manufacturing organization (CMO), specializing in oligonucleotide production.[2]
Avecia has two US FDA-audited facilities, one near Boston, MA, and the second in Cincinnati, OH. The combined capacity of these two sites allows Avecia to handle oligonucleotide programs from the pre-clinical through commercial stages. In 2016 Avecia acquired the assets of Irvine Pharmaceutical Services and Avrio Biopharmaceuticals.[2]
It was named as one of the top companies in Oligonucleotide Synthesis industry in January 2019.[3]
References[]
- ^ http://www.nitto.com www.nitto.com
- ^ a b "Nitto Denko Avecia Inc. Acquires the Businesses of Irvine Pharmaceutical Services & Avrio Biopharmaceuticals". Business Wire. 11 October 2016. Retrieved 8 February 2018.
- ^ "Oligonucleotide Synthesis Market by 2023: Top Players Like GE Healthcare, Nitto Denko Avecia, Genscript, Genedesign, Bio-Synthesis, ATDBio - Press Release - Digital Journal". www.digitaljournal.com. Retrieved 2019-02-20.
External links[]
Categories:
- Biotechnology companies of the United States